...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: New Phase 1 NCI trial
7
May 24, 2023 05:43PM

That's good news, the more paid trials the better , capacebitine is owned by Genetech, interesting, maybe another possible partner or buyer of Zenith 

Share
New Message
Please login to post a reply